Mirum Pharmaceuticals Inc
NASDAQ:MIRM

Watchlist Manager
Mirum Pharmaceuticals Inc Logo
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Watchlist
Price: 44.73 USD 2.87% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Mirum Pharmaceuticals Inc?
Write Note

Mirum Pharmaceuticals Inc
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mirum Pharmaceuticals Inc
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Effect of Foreign Exchange Rates
-$133k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Effect of Foreign Exchange Rates
$4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Effect of Foreign Exchange Rates
$52m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Effect of Foreign Exchange Rates
$32.1m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
35%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Effect of Foreign Exchange Rates
$200k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mirum Pharmaceuticals Inc
Glance View

Market Cap
2.1B USD
Industry
Biotechnology

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 137 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The firm's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The firm is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).

MIRM Intrinsic Value
44.8 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Mirum Pharmaceuticals Inc's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
-133k USD

Based on the financial report for Dec 31, 2023, Mirum Pharmaceuticals Inc's Effect of Foreign Exchange Rates amounts to -133k USD.

Back to Top